'Isolated DNA' Definition May Be Biggest Barrier to Summary Judgment at Anti-Gene Patenting Hearing
February 03, 2010
'Isolated DNA' Definition May Be Biggest Barrier to Summary Judgment at Anti-Gene Patenting Hearing
The ACLU, on behalf of plaintiffs in its anti-gene patenting case, filed a counterstatement on Jan. 20 against defendant Myriad Genetics' claims that isolated DNA molecules are patentable chemical compounds. In addition, several genetics experts have filed statements challenging many of Myriad's scientific claims.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - If US Court's Decision Against Gene Patenting Sticks, Will EU Researchers Take Up Similar Cause?
March 31, 2010 / Pharmacogenomics Reporter - Myriad Prepared to Make Small IP Sacrifice to Aussies in Light of Landmark US Patent Case
October 6, 2010 / Pharmacogenomics Reporter - Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010 / Pharmacogenomics Reporter - In Anti-Gene-Patenting Case, Myriad Files for Summary Judgment; USPTO Requests Court to Dismiss Charges
January 20, 2010 / Pharmacogenomics Reporter